- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07621471
IL-15 Enhanced NK Cell Therapy for Solid Tumors
A Single-Arm Clinical Study of IL-15 Enhanced Engineered NK Cells for Refractory Relapsed/Metastatic Solid Tumors
A single-arm, Phase 1 study evaluating safety, tolerability, and preliminary efficacy of IL-15 enhanced engineered NK cells in patients with refractory relapsed or metastatic solid tumors.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Tidig fas 1
Kontakter och platser
Studieorter
-
-
-
Chongqing, Kina
- Rekrytering
- Xinqiao Hospital
-
Kontakt:
- Xinqiao Hospital
- Telefonnummer: +86-23-68763468
- E-post: jiaqingzhu0801@outlook.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Age 18-70 years;
- ECOG 0-1;
- histopathologically confirmed metastatic or recurrent solid tumors (breast, liver, lung, etc.);
- failed prior standard therapy;
- >=1 measurable lesion per RECIST 1.1;
- adequate bone marrow, liver, kidney, and coagulation function;
- recovered from prior treatment toxicities;
- signed informed consent.
Exclusion Criteria:
- Pregnancy/lactation;
- other malignancy within 5 years (except cured localized tumors);
- active autoimmune disease or immunodeficiency;
- uncontrolled cardiovascular disease or infection;
- active TB;
- positive HBsAg/HBcAb or HCV antibody (unless viral load undetectable);
- positive syphilis antibody;
- major surgery or vaccination within 28 days;
- prior cell therapy;
- severe allergy to study drugs;
- investigator judged unsuitable.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: IL-15 Enhanced Engineered NK Cells
Single arm. Patients receive IL-15 enhanced engineered NK cells after lymphodepletion chemotherapy. |
Genetically engineered NK cells expressing IL-15. Administered intravenously. See protocol for dose details. Genetically engineered NK cells expressing IL-15 |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Incidence of Dose-Limiting Toxicity (DLT)
Tidsram: Within 28 days after first infusion
|
Within 28 days after first infusion
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Objective Response Rate (ORR)
Tidsram: Every 4 weeks for the first 6 months, then every 12 weeks through 24 months
|
Every 4 weeks for the first 6 months, then every 12 weeks through 24 months
|
|
Duration of Response (DOR)
Tidsram: From date of first documented response until date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
|
From date of first documented response until date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
|
|
Progression-Free Survival (PFS)
Tidsram: From date of enrollment until date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
|
From date of enrollment until date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
|
|
Overall Survival (OS)
Tidsram: From date of enrollment until date of death from any cause, assessed up to 24 months
|
From date of enrollment until date of death from any cause, assessed up to 24 months
|
Andra resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Expansion and persistence of IL-15 enhanced engineered NK cells and cytokine levels
Tidsram: Baseline (Day 0), Day 1, Day 3, Day 7, Day 14, Day 28, then every 4 weeks through 6 months, then every 12 weeks through 12 months
|
Baseline (Day 0), Day 1, Day 3, Day 7, Day 14, Day 28, then every 4 weeks through 6 months, then every 12 weeks through 12 months
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 2026-08-02
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .